Abstract:Introduction: Tuberous sclerosis complex (TSC) is characterized by tumor development in the brain, heart, skin, kidney and lungs. While everolimus is approved for treatment of TSC angiomyolipoma and TSC subependymal giant cell astrocytoma, responses are not complete and tumor regrowth occurs after treatment cessation. Therapies for TSC that induce a selective cytocidal response in TSC-null cells are not currently available, and are highly desirable for TSC patients. In TSC tumors loss of the TSC1/TSC2 protein complex leads to activation of mTORC1 with downstream effects on anabolism and cell growth. We hypothesized that mTORC1 activation would also enhance mRNA transcription and that this effect might create a therapeutic vulnerability. In addition, we hypothesized that rapamcyin treatment of TSC-null cells would lead to complex compensatory effects on transcription, and that synergy might be seen in co-treatment with a transcriptional inhibitor. Cyclin-dependent kinase 7 (CDK7) plays a critical role in phosphorylation of RNA polymerase II, thus regulating RNA transcription. Recent screens have identified THZ1, a selective and covalent CDK7 inhibitor, as a cytocidal compound for several cancer types. We hypothesized that THZ1 and inhibitors of CDK7 might be selectively lethal to TSC-null cells in TSC-associated tumors. Methods: Drug sensitivity assay was performed using Quant-it PicoGreen. FACS and assays of apoptosis, such as Propidium Iodide/Annexin V staining and immunoblot for cleaved caspase 3 were used to assess apoptosis. We used RNA-sequencing and metabolome profiling to assess metabolomics and transcriptional effects of THZ1, and investigate the novel hypothesis that targeting transcription triggers selective cell death in TSC-null cells. To further assess the therapeutic potential of THZ1+/-Rapamycin in TSC, In vivo treatment studies were performed using xenografts in athymic nude mice. Results: Drug sensitivity assays to THZ1+/- Rapamycin revealed selective lethality for both the TSC1-null HCV29 bladder cancer derived cell line vs. addback TSC1-HCV29 and the TSC2-null 621-101 angiomyolipoma cell line vs. TSC2 addback 621-103. The IC50 of each of TSC1/TSC2 null cells was 6-10 fold lower vs. addback lines. FACS assay of apoptosis showed 37% of HCV29 cells Annexin V+ in comparison to 3% of TSC1-HCV29 cells. IB showed cleaved Caspase 3 only in THZ1-treated TSC1-null cells. RNA-seq on samples treated with THZ1(30nm) for 6 hours identified many genes with markedly different expression: e.g. 1128 genes showed a > 5-fold lower expression in THZ1-treated HCV29 compared with THZ1-treated TSC1-HCV29 cells. Genes involved in glutathione biosynthesis pathway such as GCLC (glutamate-cysteine ligase catalytic subunit) showed an 82% reduction in mRNA levels in THZ1-treated HCV29 cells vs. TSC1-HCV 29. Metabolite analyzes confirmed that THZ1 caused a marked decrease (4 fold) in glutathione levels, and supplemental GSH-MEE rescued cell death induction in response to THZ1.THZ1(10mg/kg/twice daily) +/- Rapamycin (3mg/kg/3 days week) for 30 days markedly reduced the tumor growth rate in the in vivo TSC1-null xenograft model and prevented tumor regrowth compared to either Rapamycin or vehicle. Conclusions: These findings reveal that targeting transcriptional addiction will selectively induce cell death of TSC-null cells. We hypothesize that targeting transcription with a covalent CDK7 inhibitor has novel therapeutic benefit for patients with TSC. Citation Format: Mahsa zarei, Heng Du, Rachel E. Yan, Yubao Wang, Thingu Zhang, John M. Asara, David J. Kwiatkowski. Targeting transcriptional addiction for the treatment of TSC [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2017 Oct 26-30; Philadelphia, PA. Philadelphia (PA): AACR; Mol Cancer Ther 2018;17(1 Suppl):Abstract nr LB-B24.

Tumors with TSC mutations are sensitive to CDK7 inhibition through NRF2 and glutathione depletion.

mTORC1-mediated downregulation of COX2 restrains tumor growth caused by TSC2 deficiency

Mtor-Dependent Upregulation of Xct Blocks Melanin Synthesis and Promotes Tumorigenesis

Abstract LB-B24: Targeting Transcriptional Addiction for the Treatment of TSC

Loss of TSC1/TSC2 sensitizes immune checkpoint blockade in non–small cell lung cancer

Tumor-initiating Stem Cell Shapes Its Microenvironment into an Immunosuppressive Barrier and Pro-Tumorigenic Niche.

Mtorc1-Driven Tumor Cells Are Highly Sensitive to Therapeutic Targeting by Antagonists of Oxidative Stress

Aberrant Mtor/Autophagy/Nurr1 Signaling Is Critical For Tsc-Associated Tumor Development

A large deletion in TSC2 causes tuberous sclerosis complex by dysregulating PI3K/AKT/mTOR signaling pathway

Benign tumors in TSC are amenable to treatment by GD3 CAR T cells in mice

Tsc1 Loss Synergizes with Kras Activation in Lung Cancer Development in the Mouse and Confers Rapamycin Sensitivity

TSC Loss Distorts DNA Replication Programme and Sensitises Cells to Genotoxic Stress.

High-throughput drug screen identifies chelerythrine as a selective inducer of death in a TSC2-null setting.

TFEB drives mTORC1 hyperactivation and kidney disease in Tuberous Sclerosis Complex

Tuberous Sclerosis Complex is Required for Tumor Maintenance in MYC‐driven Burkitt's Lymphoma

Impaired autophagy due to constitutive mTOR activation sensitizes TSC2-null cells to cell death under stress.

Clinical and molecular characteristics of TSC1/2 mutant lung cancer.

Combined Targeting of Mtor and Akt Using Rapamycin and MK-2206 in the Treatment of Tuberous Sclerosis Complex

TSC2 S1365A mutation potently regulates CD8+ T cell function and differentiation and improves adoptive cellular cancer therapy

Midkine expression by stem-like tumor cells drives persistence to mTOR inhibition and an immune-suppressive microenvironment

Dysregulation of Acid Ceramidase-mediated Sphingolipid Metabolism Contributes to Tumor Progression in Tuberous Sclerosis Complex